[London, United Kingdom, Wednesday 6 April] 100,000 patients will be able to access medical cannabis products in Europe for the first time in 2022, bringing the total number of patients in Europe to 341,595. This number could rise to 1.6 million by 2026, according to new research findings.
Sales forecasts for the medical cannabis market in Europe suggest that €353 million-worth of medical cannabis will be sold on the continent in 2022, rising to €2.3 billion by 2026 – a potential 544% increase over the forecast period.
Many countries in Europe have continued to improve their medical cannabis access schemes over the last 12 months, after a slow-down due to the COVID-19 pandemic.
Patient Access and Medical Cannabis Market Growth
Exclusive data obtained by Prohibition Partners from the UK’s National Health Service (NHS) shows a 425% increase in dispensations of unlicensed medical cannabis products in England in 2021.
This swift development means the UK market could constitute about a quarter of the European medical cannabis market by 2026, or €544 million.
In Germany, the largest medical cannabis market in Europe, the market continued to grow steadily in 2021, with a 43% increase in sales of medical cannabis to pharmacies. Over 100 types of medical cannabis flower are now also available to patients in Germany.
As of March 2022, 15 countries in Europe allow for the commercial production of medical cannabis.
Further progressive legislation, liberalisation and development of a mainstreaming cannabis industry in Europe over the next five years will combine to continually improve patient access to medical cannabis, and drive exponential growth of the market, The European Cannabis Report: 7th Edition finds.
Adult-Use Cannabis in Europe
The story which is drawing most international attention, and attracting investors from North America, is the upcoming liberalisation of adult-use cannabis in Europe.
The ruling coalition of Germany has promised full legalisation and commercialisation of adult-use (recreational) cannabis in this legislative term, and legal sales of adult-use cannabis are set to start in Switzerland by the end of 2022, followed by those in the Netherlands in Q3 2023.
Prohibition Partners predicts that sales of adult-use cannabis in Europe could reach €1.5 billion by 2026, but this forecast is dependent on swift progress and full implementation of adult-use legalisation in Germany.
European cannabis industry analyst and author of The European Cannabis Report: 7th Edition, published today by Prohibition Partners, said: “Hundreds of thousands of patients in Europe are benefiting from improved access to medical cannabis, and no longer have to turn to illicit sources for their medicine. The liberalisation of adult-use cannabis in Europe could release millions of people from unnecessary criminalisation, and provide a much needed economic boost as we emerge from the COVID pandemic. Impending legalisation of adult-use cannabis in Germany, the Netherlands and Switzerland offers the first glance of this socioeconomic opportunity.”
The European Cannabis Report: 7th Edition is now available to download for free via the Prohibition Partners website.
About Prohibition Partners
Prohibition Partners provides the global cannabis industry with specialist information, data analytics and digital commerce solutions. Our B2B user base leverages our platform, brands and products to connect with the industry, make smarter decisions, maximise marketing impact and improve business performance.
For more information, questions, comment or interview requests, please contact Michael Hoban (Head of Marketing & Comms) via email: [email protected]
